Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of EpiPharm.

    Client Virtual Booth

    EPIPHARM

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    EpiPharm
    Switzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Hauptstrasse 67 Postfach 179 4102 Binningen
    Telephone
    Telephone
    +41 61 283 94 74
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://epipharm.ch/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Cyclolab and EpiPharma Form Joint Venture Company Targetrin Therapeutics to Develop Conjugated Cyclodextrin Peptide Drugs

    Details:

    Cyclolab and EpiPharma have signed an agreement to form a joint venture specialty pharmaceutical company to develop and commercialize novel conjugated Cyclodextrin – Peptide drug candidates for the treatment of debilitating CNS and Pulmonary diseases.


    Lead Product(s): Conjugated cyclodextrin-peptide therapies

    Therapeutic Area: Neurology Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Peptide

    Partner/Sponsor/Collaborator: CycloLab Cyclodextrin Research and Development Laboratory

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement January 11, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    CalciMedica Enters Research Pact with EpiPharma to Discover and Develop CRAC Channel Inhibitor Therapies

    Details:

    CalciMedica to use EpiPharma’s state-of-the-art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate the discovery and development of CalciMedica’s CRAC channel inhibitor novel drug pipeline.


    Lead Product(s): CM5480

    Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM5480

    Highest Development Status: PreclinicalProduct Type: Undisclosed

    Partner/Sponsor/Collaborator: CalciMedica

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration July 21, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-2024-05-06

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search